Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.67 |
| ▸ | FLT1 | P17948 | 7/20 | 0.67 |
| ▸ | FLT4 | P35916 | 6/20 | 0.67 |
| ▸ | FLT3 | P36888 | 2/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.67 |
| ▸ | INSR | P06213 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | MARK3 | P27448 | 1/20 | 0.67 |
| ▸ | CLK2 | P49760 | 1/20 | 0.67 |
| ▸ | GSK3A | P49840 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.67 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17442119 | 0.87 | ACVR1 (0.60) | KDRFLT1FLT4FLT3PLK4 | |
| SCHEMBL17442454 | 0.82 | PRKAB1 (0.59) | KDRFLT1FLT4FLT3PLK4 | |
| SCHEMBL2810629 | 0.80 | KDR (1.00) | KDRFLT1FLT4FLT3PLK4 | |
| SCHEMBL17442460 | 0.79 | PRKAB2 (0.82) | KDRFLT1FLT4FLT3PLK4 | |
| SCHEMBL2809221 | 0.78 | PRKAB2 (0.80) | KDRFLT1FLT4FLT3PLK4 | |
| SCHEMBL17441844 | 0.78 | KDR (0.51) | KDRFLT1FLT4PRKAB1BMP4 | |
| SCHEMBL24412157 | 0.77 | ACVR1 (0.68) | KDRFLT1FLT4PRKAB1PRKAB2 | |
| SCHEMBL17442236 | 0.76 | PRKAB2 (0.61) | KDRFLT1FLT4FLT3PLK4 | |
| SCHEMBL15996325 | 0.76 | KDR (0.76) | KDRFLT1FLT4FLT3PRKAB1 | |
| SCHEMBL13126003 | 0.76 | PRKAB1 (0.72) | KDRFLT1FLT4FLT3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BMP | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MERCK & CO., INC. | 2010-09-23 | — | — | US | disclosed |
| EP-1981509-B1 | Pyrazolo[1,5-a]pyrimidine derivatives for use in treatment of Alzheimer's disease and related conditions | MERCK SHARP & DOHME (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-1981509-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck Sharp & Dohme Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085873-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MAPT, MAP2, TTBK1 | KDR 3689/4885FLT1 3092/4885FLT4 3296/4885 |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | KDR 217/4885FLT1 155/4885FLT4 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.